Rumi is a biopharmaceutical organization targeting the genetic basis of neurological, neurodevelopmental and nephrology indications, which we approach via novel target ID & validation using our proprietary platforms of human organoids. We are building a pipeline of small molecules targeting Huntington's disease via an epigenetic mechanism, as well as genetic forms of autism spectrum disorder (FMR1, ADNP, Shank3 mutations). We have licensed an IND-ready PDE2 inhibitor for Fragile-X, beginning clinical development in 2026. Our approach combines target and drug discovery, centered on human biology & genetics.